explore -WSS

explore

author：Wikipedia 2025-09-28 00:53:44 - browse：487

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： A virus, fished out of a lake, may have saved a man’s life

WSS

3 questions for the future of Biden's cancer moonshot

The future of health care in the House

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Analysis of telehealth claims data suggest service duplication

How to fix cancer clinical trials' diversity problem

How generative AI is inspiring dreams of a health data revolution

explore

explore

Sign up for D.C. Diagnosis

focus

Medical records are filled with copy

Why Novartis is changing the name of its research labs

Virginia high school admissions case could be legal follow

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Sports medicine is finally prioritizing gender equality

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Alkermes shareholders re

Covid hospitalizations on the rise, Humana says

23andMe had bad news about my health. I wish a person had delivered it

Crinetics acromegaly drug succeeds in late

Wikipedia

FDA rejects Alnylam's heart disease treatment over insufficient data

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

ALS advocates say criticism of new drugs misses bigger picture

The future of health care in the House

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

explore

hotspot

knowledge